Sixth Annual Nephrology Symposium Evaluation

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients.	Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients. - 5	Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients. - 4	Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients. - 3	Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients. - 2	Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients. - 1	Explain the proper use of direct acting antiviral agents in the hepititis C virus (HCV) infected chronic kidney disease (CKD)/ end stage renal disease (ESRD) patients. - 0
Implement appropriate treatment of the HCV positive cryoglobulinemic patient.	Implement appropriate treatment of the HCV positive cryoglobulinemic patient. - 5	Implement appropriate treatment of the HCV positive cryoglobulinemic patient. - 4	Implement appropriate treatment of the HCV positive cryoglobulinemic patient. - 3	Implement appropriate treatment of the HCV positive cryoglobulinemic patient. - 2	Implement appropriate treatment of the HCV positive cryoglobulinemic patient. - 1	Implement appropriate treatment of the HCV positive cryoglobulinemic patient. - 0
Assess cases highlighting the pathogenesis of glomerular disease.	Assess cases highlighting the pathogenesis of glomerular disease. - 5	Assess cases highlighting the pathogenesis of glomerular disease. - 4	Assess cases highlighting the pathogenesis of glomerular disease. - 3	Assess cases highlighting the pathogenesis of glomerular disease. - 2	Assess cases highlighting the pathogenesis of glomerular disease. - 1	Assess cases highlighting the pathogenesis of glomerular disease. - 0
Identify uncommon forms of glomerular injury.	Identify uncommon forms of glomerular injury. - 5	Identify uncommon forms of glomerular injury. - 4	Identify uncommon forms of glomerular injury. - 3	Identify uncommon forms of glomerular injury. - 2	Identify uncommon forms of glomerular injury. - 1	Identify uncommon forms of glomerular injury. - 0
Implement appropriate treatment plans for challenging glomerular disease processes.	Implement appropriate treatment plans for challenging glomerular disease processes. - 5	Implement appropriate treatment plans for challenging glomerular disease processes. - 4	Implement appropriate treatment plans for challenging glomerular disease processes. - 3	Implement appropriate treatment plans for challenging glomerular disease processes. - 2	Implement appropriate treatment plans for challenging glomerular disease processes. - 1	Implement appropriate treatment plans for challenging glomerular disease processes. - 0
Identify nephrocalcinosis in patients that do not pass a kidney stone.	Identify nephrocalcinosis in patients that do not pass a kidney stone. - 5	Identify nephrocalcinosis in patients that do not pass a kidney stone. - 4	Identify nephrocalcinosis in patients that do not pass a kidney stone. - 3	Identify nephrocalcinosis in patients that do not pass a kidney stone. - 2	Identify nephrocalcinosis in patients that do not pass a kidney stone. - 1	Identify nephrocalcinosis in patients that do not pass a kidney stone. - 0
Assess and investigate the medical condition/s caused by nephrocalcinosis.	Assess and investigate the medical condition/s caused by nephrocalcinosis. - 5	Assess and investigate the medical condition/s caused by nephrocalcinosis. - 4	Assess and investigate the medical condition/s caused by nephrocalcinosis. - 3	Assess and investigate the medical condition/s caused by nephrocalcinosis. - 2	Assess and investigate the medical condition/s caused by nephrocalcinosis. - 1	Assess and investigate the medical condition/s caused by nephrocalcinosis. - 0
Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease.	Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease. - 5	Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease. - 4	Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease. - 3	Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease. - 2	Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease. - 1	Explain how nephrocalcinosis can progress in chronic kidney disease and end stage kidney disease. - 0
Assess cases highlighting the pathogenesis of glomerular disease.	Assess cases highlighting the pathogenesis of glomerular disease. - 5	Assess cases highlighting the pathogenesis of glomerular disease. - 4	Assess cases highlighting the pathogenesis of glomerular disease. - 3	Assess cases highlighting the pathogenesis of glomerular disease. - 2	Assess cases highlighting the pathogenesis of glomerular disease. - 1	Assess cases highlighting the pathogenesis of glomerular disease. - 0
Identify uncommon forms of glomerular injury.	Identify uncommon forms of glomerular injury. - 5	Identify uncommon forms of glomerular injury. - 4	Identify uncommon forms of glomerular injury. - 3	Identify uncommon forms of glomerular injury. - 2	Identify uncommon forms of glomerular injury. - 1	Identify uncommon forms of glomerular injury. - 0
Implement appropriate treatment plans for challenging glomerular disease processes.	Implement appropriate treatment plans for challenging glomerular disease processes. - 5	Implement appropriate treatment plans for challenging glomerular disease processes. - 4	Implement appropriate treatment plans for challenging glomerular disease processes. - 3	Implement appropriate treatment plans for challenging glomerular disease processes. - 2	Implement appropriate treatment plans for challenging glomerular disease processes. - 1	Implement appropriate treatment plans for challenging glomerular disease processes. - 0

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1
HCV Infection in the CKD and ESRD Patients: Who to Treat and When - David Roth, M.D.	HCV Infection in the CKD and ESRD Patients: Who to Treat and When - David Roth, M.D. - 5	HCV Infection in the CKD and ESRD Patients: Who to Treat and When - David Roth, M.D. - 4	HCV Infection in the CKD and ESRD Patients: Who to Treat and When - David Roth, M.D. - 3	HCV Infection in the CKD and ESRD Patients: Who to Treat and When - David Roth, M.D. - 2	HCV Infection in the CKD and ESRD Patients: Who to Treat and When - David Roth, M.D. - 1
Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 1 - Dominick Santoriello, M.D.	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 1 - Dominick Santoriello, M.D. - 5	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 1 - Dominick Santoriello, M.D. - 4	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 1 - Dominick Santoriello, M.D. - 3	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 1 - Dominick Santoriello, M.D. - 2	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 1 - Dominick Santoriello, M.D. - 1
Nephrocalcinosis, a poorly understood condition - Jose R. Weisinger, M.D.	Nephrocalcinosis, a poorly understood condition - Jose R. Weisinger, M.D. - 5	Nephrocalcinosis, a poorly understood condition - Jose R. Weisinger, M.D. - 4	Nephrocalcinosis, a poorly understood condition - Jose R. Weisinger, M.D. - 3	Nephrocalcinosis, a poorly understood condition - Jose R. Weisinger, M.D. - 2	Nephrocalcinosis, a poorly understood condition - Jose R. Weisinger, M.D. - 1
Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 2 - Dominick Santoriello, M.D	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 2 - Dominick Santoriello, M.D - 5	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 2 - Dominick Santoriello, M.D - 4	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 2 - Dominick Santoriello, M.D - 3	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 2 - Dominick Santoriello, M.D - 2	Pathonogenic Insights from the Renal Biopsy: A Case-Based Approach, Part 2 - Dominick Santoriello, M.D - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

No

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

No

If you checked "No,” please tell us why: *

Would you recommend this symposium to a colleague? *

If you checked "No,” please explain why you would not recommend this course: *

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

You are here

Sixth Annual Nephrology Symposium Evaluation